How we treat febrile neutropenia in patients receiving cancer chemotherapy.
Publication
, Journal Article
Lyman, GH; Rolston, KVI
Published in: J Oncol Pract
May 2010
Although improved supportive care has reduced mortality associated with febrile neutropenia, it continues to cause chemotherapy limitations, morbidity, mortality, and cost among patients with cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
May 2010
Volume
6
Issue
3
Start / End Page
149 / 152
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Rolston, K. V. I. (2010). How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract, 6(3), 149–152. https://doi.org/10.1200/JOP.091092
Lyman, Gary H., and Kenneth V. I. Rolston. “How we treat febrile neutropenia in patients receiving cancer chemotherapy.” J Oncol Pract 6, no. 3 (May 2010): 149–52. https://doi.org/10.1200/JOP.091092.
Lyman GH, Rolston KVI. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010 May;6(3):149–52.
Lyman, Gary H., and Kenneth V. I. Rolston. “How we treat febrile neutropenia in patients receiving cancer chemotherapy.” J Oncol Pract, vol. 6, no. 3, May 2010, pp. 149–52. Pubmed, doi:10.1200/JOP.091092.
Lyman GH, Rolston KVI. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010 May;6(3):149–152.
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
May 2010
Volume
6
Issue
3
Start / End Page
149 / 152
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis